

# Ruth M Risueño

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9119775/publications.pdf>

Version: 2024-02-01

39  
papers

3,487  
citations

471061

17  
h-index

414034

32  
g-index

40  
all docs

40  
docs citations

40  
times ranked

5518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lysosome-mediated chemoresistance in acute myeloid leukemia. <i>Cancer Drug Resistance (Alhambra)</i> , Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 662 1,430	0.9	2
2	Natural killer cells efficiently target multiple myeloma clonogenic tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2911-2924.	2.0	6
3	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 662 1,430	4.3	10
4	Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13536-13541.	1.6	1
5	Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 18927.	1.6	6
6	Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. <i>EBioMedicine</i> , 2019, 47, 221-234.	2.7	19
7	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. <i>Scientific Reports</i> , 2018, 8, 13883.	1.6	11
8	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. <i>Leukemia</i> , 2017, 31, 2288-2302.	3.3	20
9	Sam68 Allows Selective Targeting of Human Cancer Stem Cells. <i>Cell Chemical Biology</i> , 2017, 24, 833-844.e9.	2.5	38
10	Repositioning of bromocriptine for treatment of acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 261.	1.8	18
11	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. <i>Oncotarget</i> , 2016, 7, 23239-23250.	0.8	13
12	Biological and Therapeutic Implications of Cancer Stem Cells. , 2016, , 63-101.		0
13	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. <i>Cancer Cell International</i> , 2015, 15, 122.	1.8	4
14	G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S189-S190.	0.2	0
15	The lincRNA<i>HOTAIRM1</i>, located in the<i>HOXA</i> genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. <i>Oncotarget</i> , 2015, 6, 31613-31627.	0.8	78
16	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. <i>Blood</i> , 2015, 126, 2511-2511.	0.6	0
17	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 874-881.	0.4	16
18	XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. <i>Oncotarget</i> , 2014, 5, 4337-4346.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma. <i>Blood</i> , 2014, 124, 3467-3467.	0.6	0
20	The lincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. <i>Blood</i> , 2014, 124, 1003-1003.	0.6	0
21	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. <i>Blood</i> , 2013, 122, 1339-1339.	0.6	0
22	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2577-2577.	0.6	0
23	Inability of Human Induced Pluripotent Stem Cell-Hematopoietic Derivatives to Downregulate MicroRNAs In Vivo Reveals a Block in Xenograft Hematopoietic Regeneration. <i>Stem Cells</i> , 2012, 30, 131-139.	1.4	33
24	Identification of Drugs Including Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. <i>Cell</i> , 2012, 149, 1284-1297.	13.5	420
25	Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. <i>Blood</i> , 2011, 117, 7112-7120.	0.6	21
26	Brief Report: Ectopic Expression of Nup98-HoxA10 Augments Erythroid Differentiation of Human Embryonic Stem Cells. <i>Stem Cells</i> , 2011, 29, 736-741.	1.4	4
27	Direct conversion of human fibroblasts to multilineage blood progenitors. <i>Nature</i> , 2010, 468, 521-526.	13.7	652
28	Cooperativity Between T Cell Receptor Complexes Revealed by Conformational Mutants of CD3 $\epsilon$ . <i>Science Signaling</i> , 2009, 2, ra43.	1.6	90
29	T Cell Receptor Engagement Triggers Its CD3 $\mu$ and CD3 $\eta$ Subunits to Adopt a Compact, Locked Conformation. <i>PLoS ONE</i> , 2008, 3, e1747.	1.1	30
30	Differential antibody binding to the surface TCR $\cdot$ CD3 complex of CD4+ and CD8+ T lymphocytes is conserved in mammals and associated with differential glycosylation. <i>International Immunology</i> , 2008, 20, 1247-1258.	1.8	16
31	Targeting LSCs: powering an old tool. <i>Blood</i> , 2008, 111, 5423-5424.	0.6	1
32	Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. <i>Current Opinion in Hematology</i> , 2008, 15, 319-325.	1.2	49
33	Conformational Model. <i>Advances in Experimental Medicine and Biology</i> , 2008, 640, 103-112.	0.8	6
34	The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. <i>Clinical and Experimental Immunology</i> , 2007, 150, 375-385.	1.1	17
35	A conformation- and avidity-based proofreading mechanism for the TCR $\cdot$ CD3 complex. <i>Trends in Immunology</i> , 2006, 27, 176-182.	2.9	65
36	A conformational change senses the strength of T cell receptor-ligand interaction during thymic selection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9625-9630.	3.3	37

#	ARTICLE	IF	CITATIONS
37	Ligand-induced conformational change in the T-cell receptor associated with productive immune synapses. <i>Blood</i> , 2005, 106, 601-608.	0.6	74
38	Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. <i>Journal of Experimental Medicine</i> , 2005, 202, 493-503.	4.2	288
39	New Therapeutic Approaches for Acute Myeloid Leukaemia. <i>European Medical Journal (Chelmsford)</i> Tj ETQq1 1 0.784314 rgBT /Overl 3.0		